Biota Pharmaceuticals Inc

Type: Company
Name: Biota Pharmaceuticals Inc
First reported Apr 15 2014 - Updated Apr 16 2014 - 1 reports

Just Released: "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014"

Boston, MA -- ( SBWIRE ) -- 04/15/2014 -- Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2014', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.This report provides ... [Published SBWire - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Recently Released Market Study: Hepatitis C - Pipeline Review, H1 2014

Boston, MA -- ( SBWIRE ) -- 04/11/2014 -- Global Markets Direct's, 'Hepatitis C - Pipeline Review, H1 2014', provides an overview of the Hepatitis C's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for ... [Published SBWire - Apr 11 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 1 reports

Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies

--Foresite Capital, a growth equity firm focused on late-stage healthcare investing, today announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital commitments. Foresite Capital finances transformative ... [Published Scottrade - Apr 01 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 2 reports

3 Biotechs Expecting Top Line Phase 2 Data Mid 2014

By Kyle's Picks :When it comes to small/mid size biotech companies, it's no secret clinical data is king, often pushing the stock prices to new highs upon positive results. Biota Pharmaceuticals ( BOTA ), Inovio Pharmaceuticals ( INO ) and Athersys ( ... [Published BioPortfolio - Mar 26 2014]
First reported Feb 24 2014 - Updated Feb 25 2014 - 1 reports

Biota Pharmaceuticals, Inc. to Present at the 26th Annual ROTH Conference

About BiotaBiota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage ... [Published Stockwatch - Feb 24 2014]
First reported Dec 24 2013 - Updated Dec 24 2013 - 1 reports

Biota reports that laninamivir octanoate is approved for prevention of influenza in Japan

Biota Pharmaceuticals reported that Daiichi Sankyo Company has been granted regulatory approval in Japan to manufacture and market Inavir Dry Powder Inhaler 20mg (generic name laninamivir octanoate) for the prevention of influenza A and B. Inavir was ... [Published Pharmaceutical Business Review - Dec 24 2013]
First reported Nov 21 2013 - Updated Nov 21 2013 - 1 reports

8-K - Biota Pharmaceuticals, Inc. (0000072444) (Filer)

Filed: 2013-11-21 AccNo: 0001437749-13-015134 Size: 22 KBItem 2.05: Cost Associated with Exit or Disposal Activities ... [Published SEC Filings - Nov 21 2013]
First reported Nov 21 2013 - Updated Nov 21 2013 - 1 reports

Biota initiates additional clinical trials of laninamivir octanoate

Biota Pharmaceuticals, a biopharmaceutical company, has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (LANI), its long-acting neuraminidase inhibitor being developed for the treatment of influenza.One of the Phase 1 clinical ... [Published Pharmaceutical Business Review - Nov 21 2013]

Quotes

...a Phase III asset that is revolutionary and it has the potential to dramatically reshape the treatment of Type II diabetes," continued Tananbaum. "Universal American is another example of a classic Foresite investment with strong leadership, significant existing value and validation, and a prime position to lead the transition of care in the Medicare population."
Biota Pharmaceuticals president and CEO Russell Plumb said: "We are pleased to augment our ongoing Phase 2 IGLOO clinical trial of LANI with these important studies and anticipate initiating another Phase 1/2 clinical study next month in children aged 5-17 infected with influenza." The company expects top-line results from both of these clinical studies in the first half of 2014. Latest News

More Content

All (21) | News (10) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (11)
sort by: Date | Relevance
Just Released: "Respiratory Syncytial Virus (RS... [Published SBWire - Apr 15 2014]
Recently Released Market Study: Hepatitis C - P... [Published SBWire - Apr 11 2014]
Foresite Capital Closes $300 Million Fund II to... [Published Scottrade - Apr 01 2014]
3 Biotechs Expecting Top Line Phase 2 Data Mid ... [Published BioPortfolio - Mar 26 2014]
3 Biotechs Expecting Top Line Phase 2 Data Mid ... [Published Seeking Alpha - Mar 26 2014]
Biota Pharmaceuticals, Inc. to Present at the 2... [Published GlobeNewswire: Acquisitions News - Feb 24 2014]
Biota Pharmaceuticals, Inc. to Present at the 2... [Published Stockwatch - Feb 24 2014]
Biota Pharmaceuticals Reports Second Quarter 20... [Published GlobeNewswire: Acquisitions News - Feb 10 2014]
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Acquisitions News - Feb 03 2014]
Biota Announces Full Exercise of Over-Allotment... [Published GlobeNewswire: Acquisitions News - Jan 14 2014]
Biota Prices $25 Million Public Offering [Published GlobeNewswire: Acquisitions News - Jan 10 2014]
Biota Announces Proposed Public Offering [Published GlobeNewswire: Acquisitions News - Jan 09 2014]
Biota reports that laninamivir octanoate is app... [Published Pharmaceutical Business Review - Dec 24 2013]
Biota Reports That Laninamivir Octanoate is App... [Published GlobeNewswire: Acquisitions News - Dec 20 2013]
Biota Initiates Dosing in Phase 2 IGLOO Trial o... [Published GlobeNewswire: Acquisitions News - Dec 05 2013]
8-K - Biota Pharmaceuticals, Inc. (0000072444) ... [Published SEC Filings - Nov 21 2013]
Biota initiates additional clinical trials of l... [Published Pharmaceutical Business Review - Nov 21 2013]
Biota Initiates Additional Clinical Trials of L... [Published GlobeNewswire: Acquisitions News - Nov 19 2013]
Biota Pharmaceuticals Reports First Quarter Fin... [Published GlobeNewswire: Acquisitions News - Nov 07 2013]
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Advertising News - Oct 28 2013]
8-K - Biota Pharmaceuticals, Inc. (0000072444) ... [Published SEC Filings - Aug 16 2013]
1
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Biota Pharmaceuticals, Inc. to Present at the 2... [Published GlobeNewswire: Acquisitions News - Feb 24 2014]
Biota Pharmaceuticals Reports Second Quarter 20... [Published GlobeNewswire: Acquisitions News - Feb 10 2014]
Biota Pharmaceuticals to Host Conference Call t... [Published GlobeNewswire: Acquisitions News - Feb 03 2014]
Biota Announces Full Exercise of Over-Allotment... [Published GlobeNewswire: Acquisitions News - Jan 14 2014]
Biota Prices $25 Million Public Offering [Published GlobeNewswire: Acquisitions News - Jan 10 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.